All News

The combination is approved for the treatment of patients with metastatic castration-resistant prostate cancer, regardless of mutation status.

The coverage policy went into effect on December 28, 2023.

The study is enrolling patients with relapsed/refractory metastatic castration-resistant prostate cancer who have received at least 1 next-generation androgen receptor pathway inhibitor.

The facility will increase the production capacity of 177Lu-PSMA-617 to 250,000 doses in 2024 and beyond.

Immunotherapy initiation within 1 month of death for patients with renal cell carcinoma increased from 0.5% to 2.6% over the course of the study.

The phase 1/2a CYPIDES trial assessed the safety and preliminary efficacy of ODM-208 in heavily pretreated patients with metastatic castration-resistant prostate cancer.

Previously reported data showed promising efficacy signals and a manageable safety profile for the combination in patients with advanced solid tumors.

"When we think about a typical procedure for performing a radical cystectomy for cancer with an ileal conduit, that would typically involve lymph node dissection, and therefore CPT 51595 would be best chosen to report that combined procedure," write Jonathan Rubenstein, MD, and Mark Painter.

Data from the EV-302 trial showed a doubling of progression-free survival and overall survival with the ADC/checkpoint combination versus standard chemotherapy.

"The future of quality measurement is multiple different inputs to give us the best picture possible of the care we provide," says Timothy D. Lyon, MD, FACS.

Data from the phase 2 TheraP trial showed that 177Lu-PSMA-617 induced comparable overall survival outcomes as cabazitaxel in patients with metastatic castration-resistant prostate cancer who progressed after receiving docetaxel.

The open-label CaRe PC trial plans to enroll up to 30 adult patients with mCRPC, who will be treated across 3 dose levels of INKmune.

"All participants in the process must recognize that telehealth is a resource for rendering health care and not a different type of practicing medicine," writes Richard Cahill, JD.

Over a decade of data document a continued increase in the use of hypofractionation in patients with localized prostate cancer.

Overall, 39.1% of patients with malignant ureteral obstruction were referred to palliative care over the study period.

Over the past year, the FDA approved a multitude of new treatments and devices for use in urology practice.

"Based on the definitions from the ASA and coverage rules for Medicare, the use of nitrous oxide for urology procedures is a noncovered service," write Jonathan Rubenstein, MD, and Mark Painter.

As 2023 comes to a close, we revisit some of this year’s top content on coding in urology.

As the year comes to a close, we revisit some of this year’s top content on kidney stones.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia in urology.

As the year comes to a close, we revisit some of this year’s top content on kidney cancer.

"We found that less than 5% of people with incontinence had received a surgical intervention for their incontinence within a year of the survey," says Giulia I. Lane, MD, MS.

As the year comes to a close, we revisit some of this year’s top content on next-generation imaging agents in urology.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

As the year comes to a close, we revisit some of this year’s top content on bladder cancer.

The study is set to begin in January 2024.

"This study, using a novel technology to manage hot flashes, truly moves the field forward in improving the quality of life for men with prostate cancer,” says Alicia K. Morgans, MD, MPH.